PL1708679T3 - Farmaceutyczny preparat rozpyłowy zawierający hydrofluoroalkan i acylowaną cyklodekstrynę - Google Patents

Farmaceutyczny preparat rozpyłowy zawierający hydrofluoroalkan i acylowaną cyklodekstrynę

Info

Publication number
PL1708679T3
PL1708679T3 PL04798662T PL04798662T PL1708679T3 PL 1708679 T3 PL1708679 T3 PL 1708679T3 PL 04798662 T PL04798662 T PL 04798662T PL 04798662 T PL04798662 T PL 04798662T PL 1708679 T3 PL1708679 T3 PL 1708679T3
Authority
PL
Poland
Prior art keywords
fluor
hydro
alkane
spray formulation
pharmaceutical spray
Prior art date
Application number
PL04798662T
Other languages
English (en)
Polish (pl)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1708679T3 publication Critical patent/PL1708679T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL04798662T 2003-11-26 2004-11-24 Farmaceutyczny preparat rozpyłowy zawierający hydrofluoroalkan i acylowaną cyklodekstrynę PL1708679T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
EP04798662A EP1708679B1 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
PL1708679T3 true PL1708679T3 (pl) 2009-04-30

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04798662T PL1708679T3 (pl) 2003-11-26 2004-11-24 Farmaceutyczny preparat rozpyłowy zawierający hydrofluoroalkan i acylowaną cyklodekstrynę

Country Status (23)

Country Link
US (1) US20070104652A1 (OSRAM)
EP (1) EP1708679B1 (OSRAM)
JP (1) JP4950666B2 (OSRAM)
KR (1) KR20060118509A (OSRAM)
CN (1) CN100592908C (OSRAM)
AT (1) ATE413868T1 (OSRAM)
AU (1) AU2004294775B2 (OSRAM)
BR (1) BRPI0416992A (OSRAM)
CA (1) CA2546441C (OSRAM)
CY (1) CY1108753T1 (OSRAM)
DE (1) DE602004017783D1 (OSRAM)
DK (1) DK1708679T3 (OSRAM)
ES (1) ES2314469T3 (OSRAM)
IL (1) IL175659A (OSRAM)
MX (1) MXPA06005643A (OSRAM)
NO (1) NO20062969L (OSRAM)
NZ (1) NZ547355A (OSRAM)
PL (1) PL1708679T3 (OSRAM)
PT (1) PT1708679E (OSRAM)
SE (1) SE0303179D0 (OSRAM)
SI (1) SI1708679T1 (OSRAM)
WO (1) WO2005053637A2 (OSRAM)
ZA (1) ZA200604330B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
WO2023127219A1 (ja) * 2021-12-28 2023-07-06 リンテック株式会社 シリコーン系粘着剤、粘着シートおよび両面粘着シート

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW224942B (OSRAM) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
ATE413868T1 (de) 2008-11-15
US20070104652A1 (en) 2007-05-10
SI1708679T1 (sl) 2009-04-30
CN101087600A (zh) 2007-12-12
WO2005053637A2 (en) 2005-06-16
HK1108390A1 (zh) 2008-05-09
PT1708679E (pt) 2008-12-29
NZ547355A (en) 2009-05-31
AU2004294775A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
IL175659A (en) 2010-02-17
DE602004017783D1 (de) 2008-12-24
CA2546441A1 (en) 2005-06-16
IL175659A0 (en) 2006-09-05
AU2004294775B2 (en) 2007-12-20
DK1708679T3 (da) 2009-02-16
CY1108753T1 (el) 2014-04-09
CA2546441C (en) 2011-11-22
CN100592908C (zh) 2010-03-03
ES2314469T3 (es) 2009-03-16
MXPA06005643A (es) 2006-08-17
WO2005053637A3 (en) 2007-06-28
NO20062969L (no) 2006-08-25
EP1708679B1 (en) 2008-11-12
JP2007515401A (ja) 2007-06-14
BRPI0416992A (pt) 2007-02-06
EP1708679A2 (en) 2006-10-11
ZA200604330B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
AU2003236201A1 (en) Soluble formulations comprising monomeric insulin and acylated insulin
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2004084950A3 (en) Cell targeting methods and compositions
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
WO2004021968A3 (en) Solution for ungual application
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
MXPA05008913A (es) Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
WO2006138735A3 (en) Gel compositions for topical administration
WO2003066597A3 (en) Guanidino compounds
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
WO2007019554A3 (en) Polysaccharides for delivery of active agents
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
WO2007017176A8 (en) Wound-healing composition
IL175659A0 (en) Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
WO2007069024A3 (en) Product for treating the skin and mucous membranes, and relative method of preparation
ATE375150T1 (de) Cyclodextrine als suspensionsstabilisatoren in druckverflüssigten treibmitteln
WO2005065717A3 (de) Flüssigformulierungen von antikörperkonjugaten
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen